Literature DB >> 18436534

Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Shih-Hon Li1, Natalia V Gorlatova, Daniel A Lawrence, Bradford S Schwartz.   

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (serpin) in which the reactive center loop (RCL) spontaneously inserts into a central beta-sheet, beta-sheet A, resulting in inactive inhibitor. Available x-ray crystallographic studies of PAI-1 in an active conformation relied on the use of stabilizing mutations. Recently it has become evident that these structural models do not adequately explain the behavior of wild-type PAI-1 (wtPAI-1) in solution. To probe the structure of native wtPAI-1, we used three conformationally sensitive ligands: the physiologic cofactor, vitronectin; a monoclonal antibody, 33B8, that binds preferentially to RCL-inserted forms of PAI-1; and RCL-mimicking peptides that insert into beta-sheet A. From patterns of interaction with wtPAI-1 and the stable mutant, 14-1B, we propose a model of the native conformation of wtPAI-1 in which the bottom of the central sheet is closed, whereas the top of the beta-sheet A is open to allow partial insertion of the RCL. Because the incorporation of RCL-mimicking peptides into wtPAI-1 is accelerated by vitronectin, we further propose that vitronectin alters the conformation of the RCL to allow increased accessibility to beta-sheet A, yielding a structural hypothesis that is contradictory to the current structural model of PAI-1 in solution and its interaction with vitronectin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436534      PMCID: PMC2440609          DOI: 10.1074/jbc.M709455200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A.

Authors:  D A Lawrence; S T Olson; S Muhammad; D E Day; J O Kvassman; D Ginsburg; J D Shore
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

2.  Structure of a serpin-protease complex shows inhibition by deformation.

Authors:  J A Huntington; R J Read; R W Carrell
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

3.  Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1.

Authors:  S Stefansson; E Petitclerc; M K Wong; G A McMahon; P C Brooks; D A Lawrence
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

4.  Kinetic evidence for a two-step mechanism for the binding of chymotrypsin to alpha 1-proteinase inhibitor.

Authors:  M Bruch; J G Bieth
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

5.  Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.

Authors:  H Nar; M Bauer; J M Stassen; D Lang; A Gils; P J Declerck
Journal:  J Mol Biol       Date:  2000-03-31       Impact factor: 5.469

6.  Stability of plasminogen activator inhibitor 1 (PAI-1).

Authors:  T L Lindahl; O Sigurdardottir; B Wiman
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

7.  Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.

Authors:  J Keijer; H J Ehrlich; M Linders; K T Preissner; H Pannekoek
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

8.  Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.

Authors:  D Lawrence; L Strandberg; T Grundström; T Ny
Journal:  Eur J Biochem       Date:  1989-12-22

9.  Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes.

Authors:  N Manchanda; B S Schwartz
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

10.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

View more
  11 in total

1.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

Authors:  Lawrence C Thompson; Sumit Goswami; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

2.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

3.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

4.  Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

Authors:  Jan K Jensen; Lawrence C Thompson; Joel C Bucci; Poul Nissen; Peter G W Gettins; Cynthia B Peterson; Peter A Andreasen; J Preben Morth
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

5.  Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.

Authors:  N Garg; N Goyal; T L Strawn; J Wu; K M Mann; D A Lawrence; W P Fay
Journal:  J Thromb Haemost       Date:  2010-05-12       Impact factor: 5.824

6.  Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Ashley A Reinke; Karen L Sanders; Cory D Emal; James C Whisstock; Jeanne A Stuckey; Daniel A Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

7.  Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.

Authors:  Jianbo Wu; Lin Peng; Grainne A McMahon; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

8.  High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.

Authors:  Mary Migliorini; Shih-Hon Li; Anqi Zhou; Cory D Emal; Daniel A Lawrence; Dudley K Strickland
Journal:  J Biol Chem       Date:  2019-12-02       Impact factor: 5.157

9.  Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.

Authors:  Tihami Qureshi; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-11-25       Impact factor: 6.725

10.  Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.

Authors:  Tihami Qureshi; Sumit Goswami; Carlee S McClintock; Matthew T Ramsey; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-12-02       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.